Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All PepGen Inc. filings on SEC EDGAR ↗
PepGen Inc. entered into an underwriting agreement to sell 25,000,000 shares of common stock at a public offering price of $5.00 per share. The company expects to raise approximately $125.0 million in gross proceeds (excluding the underwriters' 30-day option for an additional 3.75 million shares) to fund clinical development and general corporate purposes.
PepGen reported positive topline results from the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 trial for PGN-EDODM1 in patients with myotonic dystrophy type 1. The data demonstrated a mean splicing correction of 46.5%, the highest reported to date in a multiple dose study, alongside functional improvements and a generally well-tolerated safety profile.
“The positive 10 mg/kg cohort results we announced today were made possible by our team’s focused execution. We are very confident in PGN-EDODM1’s potential to deliver meaningful benefit to the DM1 community, and our company ended the quarter in a strong position to advance the program to the third and highest dose cohort, which is fully enrolled.”
James McArthur, Ph.D., President and Chief Executive Officer